Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant COVID-19 Vaccine (Sf9 Cell) as Heterologous Booster vs Inactivated Vero Cell Vaccine
ChiCTR2300073665Phase 2Recruiting
- Sponsor
- Iloilo Doctors' Hospital
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by Iloilo Doctors' Hospital. Primary endpoints: Incidence of adverse drug reactions (ADRs), Geometric mean titer (GMT) of specific neutralizing antibody against SARS-CoV-2 and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300073665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073665.